| DrugRepV_0094 | BMS-777607 | Anticancer | Cancer | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (50 %) | Investigational | 28099856 |
| DrugRepV_0095 | Foretinib | Anticancer | Breast Cancer | Renal Cell Carcinoma | Breast Cancer | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (50 %) | Investigational | 28099856 |
| DrugRepV_0096 | MGCD-265 | Anticancer | Cancer | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (50 %) | Investigational | 28099856 |
| DrugRepV_0098 | Rebastinib | Anticancer | Chronic Myeloid Leukemia | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (50 %) | Investigational | 28099856 |
| DrugRepV_0099 | OSU-03012 | Anticancer | Brain cancer | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (50 %) | NA | 28099856 |
| DrugRepV_0109 | Tenovin-1 | Anticancer | Cancer | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (50 %) | NA | 28099856 |
| DrugRepV_0111 | Dioscin | Anticancer | Cancer | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (50 %) | NA | 28099856 |
| DrugRepV_0113 | Tenovin-1 | Anticancer | Cancer | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (50 %) | NA | 28099856 |
| DrugRepV_0118 | GDC-0980 | Anticancer | Solid Cancer | Breast Cancer | Prostate Cancer | Renal Cell Carcinoma | Endometrial Carcinoma | Zika virus | Mex2-81 | NA | Immunoflourescence assay | No significant effect | Investigational | 28099856 |
| DrugRepV_0131 | Obatoclax Mesylate | Anticancer | Leukemia | Myelofibrosis | Hodgkin's Lymphoma | Mantle-Cell Lymphoma | Zika virus | Mex2-81 | NA | Immunoflourescence assay | No significant effect | Investigational | 28099856 |
| DrugRepV_0141 | Tenovin-1 | Anticancer | Cancer | Zika virus | MR766 | NA | Immunoflourescence assay | Decrease (80 %) | NA | 28099856 |
| DrugRepV_0142 | Tenovin-1 | Anticancer | Cancer | Zika virus | MR766 | NA | Immunoflourescence assay | Decrease (70 %) | NA | 28099856 |
| DrugRepV_0143 | Tenovin-1 | Anticancer | Cancer | Zika virus | MR766 | NA | Immunoflourescence assay | Decrease (70 %) | NA | 28099856 |
| DrugRepV_0147 | MGCD-265 | Anticancer | Cancer | Zika virus | MR766 | NA | Immunoflourescence assay | Decrease (60 %) | Investigational | 28099856 |
| DrugRepV_0148 | MGCD-265 | Anticancer | Cancer | Zika virus | MR766 | NA | Immunoflourescence assay | No significant effect (25 %) | Investigational | 28099856 |
| DrugRepV_0149 | MGCD-265 | Anticancer | Cancer | Zika virus | MR766 | NA | Immunoflourescence assay | No significant effect (20 %) | Investigational | 28099856 |
| DrugRepV_0153 | Foretinib | Anticancer | Breast Cancer | Renal Cell Carcinoma | Breast Cancer | Zika virus | MR766 | NA | Immunoflourescence assay | Decrease (70 %) | Investigational | 28099856 |
| DrugRepV_0154 | Foretinib | Anticancer | Breast Cancer | Renal Cell Carcinoma | Breast Cancer | Zika virus | MR766 | NA | Immunoflourescence assay | No significant effect (20 %) | Investigational | 28099856 |
| DrugRepV_0155 | Foretinib | Anticancer | Breast Cancer | Renal Cell Carcinoma | Breast Cancer | Zika virus | MR766 | NA | Immunoflourescence assay | Increase (120 %) | Investigational | 28099856 |
| DrugRepV_0162 | Tenovin-1 | Anticancer | Cancer | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (95 %) | NA | 28099856 |
| DrugRepV_0163 | Tenovin-1 | Anticancer | Cancer | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (95 %) | NA | 28099856 |
| DrugRepV_0164 | Tenovin-1 | Anticancer | Cancer | Zika virus | Mex2-81 | NA | Immunoflourescence assay | No significant effect (40 %) | NA | 28099856 |
| DrugRepV_0168 | MGCD-265 | Anticancer | Cancer | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (70 %) | Investigational | 28099856 |
| DrugRepV_0169 | MGCD-265 | Anticancer | Cancer | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (70 %) | Investigational | 28099856 |
| DrugRepV_0170 | MGCD-265 | Anticancer | Cancer | Zika virus | Mex2-81 | NA | Immunoflourescence assay | No significant effect (40 %) | Investigational | 28099856 |
| DrugRepV_0174 | Foretinib | Anticancer | Breast Cancer | Renal Cell Carcinoma | Breast Cancer | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (60 %) | Investigational | 28099856 |
| DrugRepV_0175 | Foretinib | Anticancer | Breast Cancer | Renal Cell Carcinoma | Breast Cancer | Zika virus | Mex2-81 | NA | Immunoflourescence assay | Decrease (60 %) | Investigational | 28099856 |
| DrugRepV_0176 | Foretinib | Anticancer | Breast Cancer | Renal Cell Carcinoma | Breast Cancer | Zika virus | Mex2-81 | NA | Immunoflourescence assay | No significant effect (0 %) | Investigational | 28099856 |
| DrugRepV_0177 | Tenovin-1 | Anticancer | Cancer | Zika virus | Mex2-81 | NA | Real-time PCR | Decrease (80 %) | NA | 28099856 |
| DrugRepV_0178 | Tenovin-1 | Anticancer | Cancer | Zika virus | Mex2-81 | NA | Real-time PCR | Decrease (85 %) | NA | 28099856 |
| DrugRepV_0179 | Foretinib | Anticancer | Breast Cancer | Renal Cell Carcinoma | Breast Cancer | Zika virus | Mex2-81 | NA | Real-time PCR | No significant effect (30 %) | Investigational | 28099856 |
| DrugRepV_0180 | Foretinib | Anticancer | Breast Cancer | Renal Cell Carcinoma | Breast Cancer | Zika virus | Mex2-81 | NA | Real-time PCR | No significant effect (0 %) | Investigational | 28099856 |
| DrugRepV_0195 | Tenovin-1 | Anticancer | Cancer | Zika virus | Mex2-81 | NA | TCID50 assay | No significant effect (40 %) | NA | 28099856 |
| DrugRepV_0196 | Tenovin-1 | Anticancer | Cancer | Zika virus | Mex2-81 | NA | TCID50 assay | No significant effect (50 %) | NA | 28099856 |
| DrugRepV_0197 | Tenovin-1 | Anticancer | Cancer | Zika virus | Mex2-81 | NA | TCID50 assay | Decrease (75 %) | NA | 28099856 |
| DrugRepV_0219 | Bemcentinib | Anticancer | Cancer | Ebola virus | ME718-1976/Yambuku-Ecran | NA | Real-time PCR | Decrease (3.05 ± 0.75 Ct) | Investigational | 27801778 |
| DrugRepV_0220 | Bemcentinib | Anticancer | Cancer | Ebola virus | ME718-1976/Yambuku-Ecran | NA | Real-time PCR | Increase (?1.83 ± 1.13 Ct) | Investigational | 27801778 |
| DrugRepV_0253 | Bemcentinib | Anticancer | Cancer | Ebola virus | ME718-1976/Yambuku-Ecran | NA | Real-time PCR | Decrease (0.90 ± 0.15 Ct) | Investigational | 27801778 |
| DrugRepV_0260 | Bemcentinib | Anticancer | Cancer | Ebola virus | ME718-1976/Yambuku-Ecran | NA | NA | No significant effect | Investigational | 27801778 |
| DrugRepV_0296 | Dinaciclib | Anticancer | Cancer | Influenza virus | A/Anhui/1/ 2013 |  | Immunoflourescence assay | Decrease (50 %) | Investigational | 26192013 |
| DrugRepV_0297 | Dinaciclib | Anticancer | Cancer | Influenza virus | A/California/04/09 | | Immunoflourescence assay | Decrease (50 %) | Investigational | 26192013 |
| DrugRepV_0298 | Dinaciclib | Anticancer | Cancer | Influenza virus | A/Philippines/2/82-X79 | | Immunoflourescence assay | Decrease (50 %) | Investigational | 26192013 |
| DrugRepV_0299 | Flavopiridol | Anticancer | Esophageal cancer | Leukemia (lymphoid) | Lung cancer | Liver cancer | Influenza virus | A/Anhui/1/ 2013 | | Immunoflourescence assay | Decrease (50 %) | Experimental, Investigational | 26192013 |
| DrugRepV_0300 | Flavopiridol | Anticancer | Esophageal cancer | Leukemia (lymphoid) | Lung cancer | Liver cancer | Influenza virus | A/California/04/09 | | Immunoflourescence assay | Decrease (50 %) | Experimental, Investigational | 26192013 |
| DrugRepV_0301 | Flavopiridol | Anticancer | Esophageal cancer | Leukemia (lymphoid) | Lung cancer | Liver cancer | Influenza virus | A/Philippines/2/82-X79 | | Immunoflourescence assay | Decrease (50 %) | Experimental, Investigational | 26192013 |
| DrugRepV_0305 | Dinaciclib | Anticancer | Cancer | Influenza virus | A/Mississippi/3/01 wt | | TCID50 assay | Decrease (1.5 Log10 virus titer (TCID50/ml)) | Investigational | 26192013 |
| DrugRepV_0306 | Dinaciclib | Anticancer | Cancer | Influenza virus | A/Mississippi/3/01 H275Y | | TCID50 assay | Decrease (>1 Log10 virus titer (TCID50/ml)) | Investigational | 26192013 |
| DrugRepV_0307 | Flavopiridol | Anticancer | Esophageal cancer | Leukemia (lymphoid) | Lung cancer | Liver cancer | Influenza virus | A/Mississippi/3/01 wt | | TCID50 assay | Decrease (1.5 Log10 virus titer (TCID50/ml)) | Experimental, Investigational | 26192013 |
| DrugRepV_0308 | Flavopiridol | Anticancer | Esophageal cancer | Leukemia (lymphoid) | Lung cancer | Liver cancer | Influenza virus | A/Mississippi/3/01 H275Y | | TCID50 assay | Decrease (~1 Log10 virus titer (TCID50/ml)) | Experimental, Investigational | 26192013 |
| DrugRepV_0311 | Dinaciclib | Anticancer | Cancer | Influenza virus | A/Mississippi/3/01 wt | | Immunoflourescence assay | Decrease (>95 %) | Investigational | 26192013 |
| DrugRepV_0312 | Dinaciclib | Anticancer | Cancer | Influenza virus | A/Mississippi/3/01 H275Y | | Immunoflourescence assay | Decrease (95 %) | Investigational | 26192013 |
| DrugRepV_0313 | Flavopiridol | Anticancer | Esophageal cancer | Leukemia (lymphoid) | Lung cancer | Liver cancer | Influenza virus | A/Mississippi/3/01 wt | | Immunoflourescence assay | Decrease (>95 %) | Experimental, Investigational | 26192013 |
| DrugRepV_0314 | Flavopiridol | Anticancer | Esophageal cancer | Leukemia (lymphoid) | Lung cancer | Liver cancer | Influenza virus | A/Mississippi/3/01 H275Y | | Immunoflourescence assay | Decrease (90 %) | Experimental, Investigational | 26192013 |
| DrugRepV_0522 | Nocodazole | Anticancer | NA | Ebola virus | EBOVBlaVP40 | NA | Fluorescence-based assay | Decrease (50 %) | Experimental | 26038505 |
| DrugRepV_1041 | Floxuridine | Anticancer | Gastrointestinal adenocarcinomas | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (50.32 %) | Approved | 27476412 |
| DrugRepV_1580 | Floxuridine | Anticancer | Gastrointestinal adenocarcinomas | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (45 %) | Approved | 26217313 |
| DrugRepV_1626 | Etalocib | Anticancer | Cancer | Influenza virus | A/Anhui/01/2013 | | Transcriptomic response-DEG | Decrease | Investigational | 24991006 |
| DrugRepV_1633 | Etalocib | Anticancer | Cancer | Influenza virus | A/Anhui/01/2013 | | Transcriptomic response-DEG | Decrease | Investigational | 24991006 |
| DrugRepV_1685 | Piperine | Anticancer | Multiple Myeloma | Deglutition Disorders | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Investigational | 27571349 |
| DrugRepV_1696 | OSI-930 | Anticancer | Solid tumors | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Investigational | 27571349 |
| DrugRepV_1756 | Piperine | Anticancer | Multiple Myeloma | Deglutition Disorders | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Investigational | 27571349 |
| DrugRepV_1767 | OSI-930 | Anticancer | Solid tumors | Zika virus | MR766 | NA | Cell viability assay | Decrease (71.2 %) | Investigational | 27571349 |
| DrugRepV_1827 | Piperine | Anticancer | Multiple Myeloma | Deglutition Disorders | Zika virus | MR766 | NA | Cell viability assay | No significant effect | Investigational | 27571349 |
| DrugRepV_1838 | OSI-930 | Anticancer | Solid tumors | Zika virus | MR766 | NA | Cell viability assay | No significant effect | Investigational | 27571349 |
| DrugRepV_1892 | Seliciclib | Anticancer | Breast cancer | Lung cancer | Lymphoma | Multiple myeloma | Leukemia | Zika virus | FSS13026 | NA | NA | Decrease (50 %) | Investigational | 27571349 |
| DrugRepV_1894 | PHA-793887 | Anticancer | Cancer | Zika virus | FSS13026 | NA | NA | Decrease (50 %) | NA | 27571349 |
| DrugRepV_1896 | BS-194 | Anticancer | Cancer | Zika virus | FSS13026 | NA | NA | Decrease (50 %) | NA | 27571349 |
| DrugRepV_1898 | Dinaciclib | Anticancer | Cancer | Zika virus | FSS13026 | NA | NA | Decrease (50 %) | Investigational | 27571349 |
| DrugRepV_1902 | PHA-793887 | Anticancer | Cancer | Zika virus | FSS13026 | NA | Western blot | Decrease (Decrease Band intensity) | NA | 27571349 |
| DrugRepV_1903 | Dinaciclib | Anticancer | Cancer | Zika virus | FSS13026 | NA | Western blot | Decrease (Decrease Band intensity) | Investigational | 27571349 |
| DrugRepV_1904 | Seliciclib | Anticancer | Breast cancer | Lung cancer | Lymphoma | Multiple myeloma | Leukemia | Zika virus | FSS13026 | NA | Western blot | Decrease (Decrease Band intensity) | Investigational | 27571349 |
| DrugRepV_1907 | PHA-793887 | Anticancer | Cancer | Zika virus | PRVABC-59 (2015 Puerto Rican strain) | NA | Western blot | Decrease (Decrease Band intensity) | NA | 27571349 |
| DrugRepV_1908 | Dinaciclib | Anticancer | Cancer | Zika virus | PRVABC-59 (2015 Puerto Rican strain) | NA | Western blot | Decrease (Decrease Band intensity) | Investigational | 27571349 |
| DrugRepV_1909 | Seliciclib | Anticancer | Breast cancer | Lung cancer | Lymphoma | Multiple myeloma | Leukemia | Zika virus | PRVABC-59 (2015 Puerto Rican strain) | NA | Western blot | Decrease (Decrease Band intensity) | Investigational | 27571349 |
| DrugRepV_2022 | Securinine | Anticancer | NA | Ebola virus | Zaire strain-pEBOV | NA | Firefly luciferase assay | Decrease (50 %) | NA | 26585243 |
| DrugRepV_2254 | Resveratrol | Anticancer | Herpes labialis infections (cold sores) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (5.82320541 %) | Approved, Experimental, Investigational | 27742486 |
| DrugRepV_2524 | Gimeracil | Anticancer | Gastric cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.4276036 %) | Approved | 27742486 |
| DrugRepV_2572 | Camptothecin | Anticancer | Cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.2458719 %) | Approved | 27742486 |
| DrugRepV_2616 | Floxuridine | Anticancer | Gastrointestinal adenocarcinomas | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.7449704 %) | Approved | 27742486 |
| DrugRepV_2919 | Doxifluridine | Anticancer | Stomach cancer | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-11.000576 %) | Investigational | 27742486 |
| DrugRepV_2995 | Flavaglines FL3 | Anticancer | NA | Chikungunya virus | NA | NA | Plaque assay | Decrease (45 %) | NA | 25643977 |
| DrugRepV_2996 | Flavaglines FL3 | Anticancer | NA | Chikungunya virus | NA | NA | Plaque assay | Decrease (50 %) | NA | 25643977 |
| DrugRepV_2997 | Flavaglines FL23 | Anticancer | NA | Chikungunya virus | NA | NA | Plaque assay | Decrease (25 %) | NA | 25643977 |
| DrugRepV_2998 | Flavaglines FL23 | Anticancer | NA | Chikungunya virus | NA | NA | Plaque assay | Decrease (40 %) | NA | 25643977 |
| DrugRepV_3001 | Flavaglines FL3 | Anticancer | NA | Chikungunya virus | NA | NA | Plaque assay | Decrease (50 %) | NA | 25643977 |
| DrugRepV_3041 | Fenretinide | Anticancer | Prostate cancer | Breast cancer | Macular degeneration | Chikungunya virus | LR2006 OPY1 | NA | Luciferase reporter assay | Decrease (50 %) | Investigational | 26752081 |
| DrugRepV_3046 | Fenretinide | Anticancer | Prostate cancer | Breast cancer | Macular degeneration | Chikungunya virus | LR2006 OPY1 | NA | Luciferase reporter assay | Decrease (50 %) | Investigational | 26752081 |
| DrugRepV_3054 | Fenretinide | Anticancer | Prostate cancer | Breast cancer | Macular degeneration | Chikungunya virus | CHIKV-Rluc | NA | Luciferase reporter assay | Decrease (40 %) | Investigational | 26752081 |
| DrugRepV_3080 | Fenretinide | Anticancer | Prostate cancer | Breast cancer | Macular degeneration | Chikungunya virus | CHIKV-Rluc | NA | Plaque assay | No significant effect (No significant effect Log) | Investigational | 26752081 |
| DrugRepV_3437 | Obatoclax | Anticancer | Leukemia | Myelofibrosis | Hodgkin's Lymphoma | Mantle-Cell Lymphoma | Influenza virus | PR8-GFP | | GFP assay | Decrease (50 %) | Investigational | 22910914 |
| DrugRepV_3445 | Obatoclax | Anticancer | Leukemia | Myelofibrosis | Hodgkin's Lymphoma | Mantle-Cell Lymphoma | Influenza virus | PR8-GFP | | GFP assay | Decrease (50 %) | Investigational | 22910914 |
| DrugRepV_3458 | Hesperadin | Anticancer | NA | Influenza virus | A/Texas/4/2009 (H1N1) | | Plaque assay | Decrease (50 %) | Approved, Investigational | 28885544 |
| DrugRepV_3459 | Hesperadin | Anticancer | NA | Influenza virus | A/North Carolina/39/2009 (H1N1) | | Plaque assay | Decrease (50 %) | Approved, Investigational | 28885544 |
| DrugRepV_3460 | Hesperadin | Anticancer | NA | Influenza virus | A/Washington/29/2009 (H1N1) | | Plaque assay | Decrease (50 %) | Approved, Investigational | 28885544 |
| DrugRepV_3461 | Hesperadin | Anticancer | NA | Influenza virus | A/California/02/2014 (H3N2) | | Plaque assay | Decrease (50 %) | Approved, Investigational | 28885544 |
| DrugRepV_3462 | Hesperadin | Anticancer | NA | Influenza virus | A/Texas/12/2007 (H3N2) | | Plaque assay | Decrease (50 %) | Approved, Investigational | 28885544 |
| DrugRepV_3463 | Hesperadin | Anticancer | NA | Influenza virus | A/WSN/1933 (H1N1) | | Plaque assay | Decrease (50 %) | Approved, Investigational | 28885544 |
| DrugRepV_3464 | Hesperadin | Anticancer | NA | Influenza virus | A/California/07/2009 (H1N1) | | Plaque assay | Decrease (50 %) | Approved, Investigational | 28885544 |
| DrugRepV_3465 | Hesperadin | Anticancer | NA | Influenza virus | B/Wisconsin/1/2010 (Yamagata) | | Plaque assay | Decrease (50 %) | Approved, Investigational | 28885544 |
| DrugRepV_3466 | Hesperadin | Anticancer | NA | Influenza virus | B/brisbane/60/2008 (victoria) | | Plaque assay | Decrease (50 %) | Approved, Investigational | 28885544 |
| DrugRepV_3467 | Hesperadin | Anticancer | NA | Influenza virus | A/California/07/2009 (H1N1) | | Plaque assay | Decrease (2.5 Log) | Approved, Investigational | 28885544 |
| DrugRepV_3468 | Hesperadin | Anticancer | NA | Influenza virus | A/Washington/39/2009 (H1N1) | | Plaque assay | Decrease (2.5 Log) | Approved, Investigational | 28885544 |
| DrugRepV_3469 | Hesperadin | Anticancer | NA | Influenza virus | B/Wisconsin/1/2010 (Yamagata) | | Plaque assay | Decrease (3.4 Log) | Approved, Investigational | 28885544 |
| DrugRepV_3726 | OSU-03012 | Anticancer | Brain cancer | Lassa virus | NA | NA | NA | Decrease | NA | 25986249 |
| DrugRepV_3733 | OSU-03012 | Anticancer | Brain cancer | Lassa virus | NA | NA | Immunoflourescence assay | Decrease (50 %) | NA | 25986249 |
| DrugRepV_3734 | OSU-03012 | Anticancer | Brain cancer | Nipah virus | NA | NA | GFP assay | Decrease (50 %) | NA | 25986249 |
| DrugRepV_3735 | OSU-03012 | Anticancer | Brain cancer | Ebola virus | NA | NA | GFP assay | Decrease (50 %) | NA | 25986249 |
| DrugRepV_3736 | OSU-03012 | Anticancer | Brain cancer | Marburg virus | NA | NA | GFP assay | Decrease (50 %) | NA | 25986249 |
| DrugRepV_3737 | OSU-03012 | Anticancer | Brain cancer | Crimean-Congo hemorrhagic fever virus | NA | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | NA | 25986249 |
| DrugRepV_3741 | OSU-03012 | Anticancer | Brain cancer | Lassa virus | NA | NA | RT-PCR | Decrease (50 %) | NA | 25986249 |
| DrugRepV_3743 | OSU-03012 | Anticancer | Brain cancer | Ebola virus | NA | NA | RT-PCR | Decrease (50 %) | NA | 25986249 |
| DrugRepV_4497 | Ranpirnase | Anticancer | Cancer | Ebola virus | Kikwit | NA | NA | Decrease (50 %) | Investigational | 27350309 |
| DrugRepV_4498 | Ranpirnase | Anticancer | Cancer | Ebola virus | Kikwit | NA | Fluorescence-based assay | Decrease | Investigational | 27350309 |
| DrugRepV_4499 | Ranpirnase | Anticancer | Cancer | Ebola virus | Kikwit | NA | NA | Increase | Investigational | 27350309 |
| DrugRepV_4622 | Infergen | Anticancer | Hairy cell leukemia | Malignant melanoma | AIDS-related Kaposi's sarcom | Severe acute respiratory syndrome coronavirus | v2163 | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved, Investigational | 19853271 |
| DrugRepV_4623 | Infergen | Anticancer | Hairy cell leukemia | Malignant melanoma | AIDS-related Kaposi's sarcom | Severe acute respiratory syndrome coronavirus | Urbani | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved, Investigational | 19853271 |
| DrugRepV_4720 | Saracatinib | Anticancer | Osteosarcoma | Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer | Middle East respiratory syndrome coronavirus | EMC/2012 strain | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Investigational | 29795047 |
| DrugRepV_4721 | Sotrastaurin | Anticancer | Uveal Melanoma | Richter Syndrome | Prolymphocytic Leukemia | Recurrent Mantle Cell Lymphoma Recurrent Small Lymphocytic Lymphoma | Middle East respiratory syndrome coronavirus | EMC/2012 strain | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Investigational | 29795047 |
| DrugRepV_4744 | Selumetinib | Anticancer | Melanoma | Solid Tumour | Breast Cancer | Non Small Cell Lung Cancer | Middle East respiratory syndrome coronavirus | NA | NA | Plaque assay | Decrease (70 %) | Investigational | 25487801 |
| DrugRepV_5123 | Cordycepine | Anticancer | Leukemia | Crimean-Congo hemorrhagic fever virus | CCHFV/ZsG | NA | Fluorescence-based assay | No significant effect (12 %) | Investigational | 29024765 |
| DrugRepV_5612 | Tenovin-1 | Anticancer | Cancer | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (90 %) | NA | 28099856 |
| DrugRepV_5613 | Tenovin-1 | Anticancer | Cancer | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (95 %) | NA | 28099856 |
| DrugRepV_5614 | Tenovin-1 | Anticancer | Cancer | Dengue virus | New Guinea C | | Immunoflourescence assay | No significant effect (10 %) | NA | 28099856 |
| DrugRepV_5618 | MGCD-265 | Anticancer | Cancer | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (70 %) | Investigational | 28099856 |
| DrugRepV_5619 | MGCD-265 | Anticancer | Cancer | Dengue virus | New Guinea C | | Immunoflourescence assay | No significant effect (25 %) | Investigational | 28099856 |
| DrugRepV_5620 | MGCD-265 | Anticancer | Cancer | Dengue virus | New Guinea C | | Immunoflourescence assay | No significant effect (20 %) | Investigational | 28099856 |
| DrugRepV_5624 | Foretinib | Anticancer | Breast Cancer | Renal Cell Carcinoma | Breast Cancer | Dengue virus | New Guinea C | | Immunoflourescence assay | Decrease (80 %) | Investigational | 28099856 |
| DrugRepV_5625 | Foretinib | Anticancer | Breast Cancer | Renal Cell Carcinoma | Breast Cancer | Dengue virus | New Guinea C | | Immunoflourescence assay | No significant effect (25 %) | Investigational | 28099856 |
| DrugRepV_5626 | Foretinib | Anticancer | Breast Cancer | Renal Cell Carcinoma | Breast Cancer | Dengue virus | New Guinea C | | Immunoflourescence assay | Increase (120 %) | Investigational | 28099856 |
| DrugRepV_5753 | Fenretinide | Anticancer | Prostate cancer | Breast cancer | Macular degeneration | Dengue virus | NGC | | Plaque assay | Decrease (1000 Fold) | Investigational | 25313218 |
| DrugRepV_5754 | Fenretinide | Anticancer | Prostate cancer | Breast cancer | Macular degeneration | Dengue virus | NGC | | Western blot | Decrease (100 %) | Investigational | 25313218 |
| DrugRepV_5755 | Fenretinide | Anticancer | Prostate cancer | Breast cancer | Macular degeneration | Dengue virus | NGC | | Western blot | Decrease (100 %) | Investigational | 25313218 |
| DrugRepV_5756 | Fenretinide | Anticancer | Prostate cancer | Breast cancer | Macular degeneration | Dengue virus | NGC | | Plaque assay | Decrease (50 %) | Investigational | 25313218 |
| DrugRepV_5757 | Fenretinide | Anticancer | Prostate cancer | Breast cancer | Macular degeneration | Dengue virus | NGC | | Plaque assay | Decrease (3.2 Logs) | Investigational | 25313218 |
| DrugRepV_5758 | Fenretinide | Anticancer | Prostate cancer | Breast cancer | Macular degeneration | Dengue virus | NGC | | Plaque assay | Decrease (1 Logs) | Investigational | 25313218 |
| DrugRepV_5759 | Fenretinide | Anticancer | Prostate cancer | Breast cancer | Macular degeneration | Dengue virus | NGC | | Plaque assay | Decrease (1 Logs) | Investigational | 25313218 |
| DrugRepV_5760 | Fenretinide | Anticancer | Prostate cancer | Breast cancer | Macular degeneration | Dengue virus | NGC | | Plaque assay | Decrease (0 Logs) | Investigational | 25313218 |
| DrugRepV_5767 | Fenretinide | Anticancer | Prostate cancer | Breast cancer | Macular degeneration | Dengue virus | D2Y98P | | Plaque assay | Decrease (1.73 Logs) | Investigational | 25313218 |
| DrugRepV_5998 | Saracatinib | Anticancer | Cancer | Dengue virus | New Guinea | | Plaque assay | Decrease (2 Log (pfu/ml)) | Investigational | 17360676 |
| DrugRepV_5999 | Saracatinib | Anticancer | Cancer | Dengue virus | New Guinea | | Plaque assay | Decrease (2 Log (pfu/ml)) | Investigational | 17360676 |
| DrugRepV_6000 | Saracatinib | Anticancer | Cancer | Dengue virus | New Guinea | | Plaque assay | Decrease (2 Log (pfu/ml)) | Investigational | 17360676 |
| DrugRepV_6019 | Saracatinib | Anticancer | Cancer | Dengue virus | New Guinea C | | Focus forming assay | Decrease (90 %) | Investigational | 23616652 |
| DrugRepV_6022 | Saracatinib | Anticancer | Cancer | Dengue virus | New Guinea C | | Northern blot | Decrease (60 AU (Arbitrary units)) | Investigational | 23616652 |
| DrugRepV_6024 | Saracatinib | Anticancer | Cancer | Dengue virus | New Guinea C | | Northern blot | Decrease (65 AU (Arbitrary units)) | Investigational | 23616652 |
| DrugRepV_6026 | Saracatinib | Anticancer | Cancer | Dengue virus | New Guinea C | | Western blot | Decrease (Decrease expression of C protein Band Intensity) | Investigational | 23616652 |
| DrugRepV_6027 | Saracatinib | Anticancer | Cancer | Dengue virus | New Guinea C | | Western blot | Decrease (Decrease expression of E protein Band Intensity) | Investigational | 23616652 |
| DrugRepV_6028 | Saracatinib | Anticancer | Cancer | Dengue virus | New Guinea C | | Western blot | Decrease (Decrease expression of NS3 and NS5 protein Band Intensity) | Investigational | 23616652 |
| DrugRepV_6032 | Saracatinib | Anticancer | Cancer | Dengue virus | New Guinea C | | Luciferase reporter assay | Decrease (1 Log) | Investigational | 23616652 |
| DrugRepV_6485 | Saracatinib | Anticancer | Osteosarcoma | Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer | Human immunodeficiency virus | HXB2 luciferase reporter virus | | Luciferase reporter assay | Decrease (60 %) | Investigational | 26807966 |
| DrugRepV_6486 | Saracatinib | Anticancer | Osteosarcoma | Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer | Human immunodeficiency virus | JR-FL luciferase reporter virus | | Luciferase reporter assay | Decrease (90 %) | Investigational | 26807966 |
| DrugRepV_6489 | Src inhibitor-1 | Anticancer | Pancreatic cancer | Breast cancer | Stomach cancer | Human immunodeficiency virus | HXB2 luciferase reporter virus | | Luciferase reporter assay | Decrease (60 %) | NA | 26807966 |
| DrugRepV_6490 | Src inhibitor-1 | Anticancer | Pancreatic cancer | Breast cancer | Stomach cancer | Human immunodeficiency virus | JR-FL luciferase reporter virus | | Luciferase reporter assay | Decrease (75 %) | NA | 26807966 |
| DrugRepV_7056 | Fenretinide | Anticancer | Prostate cancer | Breast cancer | Macular degeneration | West Nile virus | NA | | Plaque assay | Decrease (3 Logs) | Investigational | 25313218 |
| DrugRepV_7057 | Fenretinide | Anticancer | Prostate cancer | Breast cancer | Macular degeneration | West Nile virus | NA | | Real-time PCR | Decrease (2 Fold) | Investigational | 25313218 |
| DrugRepV_7058 | Fenretinide | Anticancer | Prostate cancer | Breast cancer | Macular degeneration | Polio virus | NA | | Plaque assay | Decrease | Investigational | 25313218 |
| DrugRepV_7101 | Fenretinide | Anticancer | Prostate cancer | Breast cancer | Macular degeneration | Yellow fever virus | 17D | | Plaque assay | Decrease (3 Log) | Investigational | 26752081 |
| DrugRepV_7399 | Resveratrol | Anticancer | Herpes labialis infections (cold sores) | West Nile virus | NY-99 | | Plaque assay | Decrease (0.6 Log) | Approved, Experimental, Investigational | 28507114 |
| DrugRepV_7474 | Hypericin | Anticancer | Cutaneous T-cell Lymphoma | West Nile virus | New York | | Visual assay | Decrease (50 %) | Investigational | 12076755 |
| DrugRepV_7477 | Hypericin | Anticancer | Cutaneous T-cell Lymphoma | West Nile virus | New York | | NR assay | Decrease (50 %) | Investigational | 12076755 |
| DrugRepV_7916 | Obatoclax | Anticancer | Leukemia | Myelofibrosis | Hodgkin's Lymphoma | Mantle-Cell Lymphoma | Influenza virus | A/Puerto Rico/8/34 | | MTT assay | Decrease (50 %) | Investigational | 31941776 |
| DrugRepV_7917 | OSU-03012 | Anticancer | Brain cancer | Influenza virus | A/Puerto Rico/8/34 | | MTT assay | Decrease (50 %) | NA | 31941776 |
| DrugRepV_8138 | Tenovin-1 | Anticancer | Cancer | Vaccinia virus | NA | | NA | Decrease (32 %) | NA | 32708182 |
| DrugRepV_8154 | Floxuridine | Anticancer | Gastrointestinal adenocarcinomas | Vaccinia virus | NA | | NA | Decrease (62.6 %) | Approved | 32708182 |
| DrugRepV_8216 | OSI-930 | Anticancer | Solid tumors | Vaccinia virus | NA | | NA | Decrease (43.5 %) | Investigational | 32708182 |
| DrugRepV_8226 | Nocodazole | Anticancer | NA | Vaccinia virus | NA | | NA | Decrease (76.2 %) | Experimental | 32708182 |